J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Jafron Biomedical Co Ltd
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jafron Biomedical Co Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Short-Term Debt
ÂĄ338.8m
CAGR 3-Years
N/A
CAGR 5-Years
73%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Short-Term Debt
ÂĄ70m
CAGR 3-Years
88%
CAGR 5-Years
46%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Short-Term Debt
ÂĄ428.7m
CAGR 3-Years
24%
CAGR 5-Years
33%
CAGR 10-Years
24%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Short-Term Debt
ÂĄ3.5m
CAGR 3-Years
N/A
CAGR 5-Years
-15%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Short-Term Debt
ÂĄ1.5B
CAGR 3-Years
5%
CAGR 5-Years
1%
CAGR 10-Years
55%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Short-Term Debt
ÂĄ328.2m
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.1B CNY
Industry
Health Care

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.

Intrinsic Value
47.02 CNY
Undervaluation 36%
Intrinsic Value
Price
J

See Also

What is Jafron Biomedical Co Ltd's Short-Term Debt?
Short-Term Debt
338.8m CNY

Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Short-Term Debt amounts to 338.8m CNY.

What is Jafron Biomedical Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 5Y
73%

Over the last year, the Short-Term Debt growth was -37%.

Back to Top